Dr. Bardia emphasizes the importance of considering T-DXd as the first-line option for patients with aggressive disease, discussing the urgency and strategic advantage of employing highly effective therapies upfront.
Topics Covered:
• First-line T-DXd consideration
• Risks of delaying highly effective treatments
• Treatment sequencing and patient outcomes
